Compass Pathways is trading 5.2% down today at $12.62 as investors lock in profits following a significant rally driven by Phase 3 trial results.
- The stock recently surged on positive six-month COMP006 data for COMP360 in treatment-resistant depression, but momentum is cooling as traders reassess risk around upcoming durability data.
- Today's decline aligns with broader weakness in high-beta biotech stocks amid a risk-off market environment, with no new company-specific negative catalysts reported.